• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Lettmann Jason

    3/23/26 4:05:08 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALXO alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Lettmann Jason

    (Last)(First)(Middle)
    C/O ALX ONCOLOGY HOLDINGS INC.
    323 ALLERTON AVENUE

    (Street)
    SOUTH SAN FRANCISCO CALIFORNIA 94080

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    ALX ONCOLOGY HOLDINGS INC [ ALXO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    XOfficer (give title below)Other (specify below)
    CHIEF EXECUTIVE OFFICER
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    03/19/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock03/19/2026S(1)12,311D$2.17293,609D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    1. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of perfomance-based restricted stock units.
    /s/ Shelly Pinto, by power of attorney03/23/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $ALXO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALXO

    DatePrice TargetRatingAnalyst
    3/19/2026$5.00Overweight
    Wells Fargo
    3/6/2026$6.00Buy
    UBS
    11/13/2025$4.00Buy
    Jefferies
    3/6/2025$2.00 → $3.00Hold → Buy
    Jefferies
    12/19/2024$12.00 → $2.00Buy → Hold
    Jefferies
    3/8/2024$10.00 → $14.00Buy → Hold
    Stifel
    12/8/2023$8.00 → $18.00Hold → Buy
    Jefferies
    3/1/2022$60.00 → $36.00Buy
    Stifel
    More analyst ratings

    $ALXO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by ALX Oncology Holdings Inc.

    SCHEDULE 13D/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

    5/27/26 4:17:57 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by ALX Oncology Holdings Inc.

    SCHEDULE 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

    5/15/26 4:15:41 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by ALX Oncology Holdings Inc.

    SCHEDULE 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

    5/15/26 4:05:47 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Goodman Corey S bought $4,999,999 worth of shares (3,184,713 units at $1.57) (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    2/4/26 4:15:59 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Lettmann Jason bought $99,352 worth of shares (92,233 units at $1.08), increasing direct ownership by 43% to 305,121 units (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    9/18/25 4:23:19 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Shantharam Harish bought $58,402 worth of shares (75,000 units at $0.78) (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    8/20/25 4:02:05 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York

    SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ((", NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in a fireside chat presentation at the 2026 Jefferies Global Healthcare Conference in New York. The details of the meeting are as follows: 2026 Jefferies Global Healthcare Conference in New York Format: Fireside Chat PresentationDate: June 3, 2026Time: 5:30 PM ETWebcast link: Available here The webcast of the 2026 Jefferies Global Healthcare Conference presentation can be accessed by visi

    6/1/26 8:00:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

    - Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination - - Evorpacept data from two independent HER2-positive trials strengthens confidence in the CD47-selection hypothesis and potentially derisks path forward in HER2-positive breast cancer - - Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer is on track for topline data mid-2027 - - Phase 1 trial evaluating ALX2004 continues to enroll well, on track for safety data in 2H 2026 -

    5/8/26 8:00:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression

    - Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - Findings are consistent with previous results from the randomized ASPEN-06 trial in HER2-positive gastric cancer, which indicated CD47 expression could potentially serve as an important predictive biomarker of evorpacept activity - - ALX Oncology will host a webcast on May 8 to report first quarter 2026 financial results; breast cancer expert will discuss the evorpacept + zanidatamab trial results in detail - SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (NASDAQ:ALXO), a clinical-stage biotechnology compa

    5/7/26 8:00:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Knight Jeff E.

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    4/17/26 4:15:03 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Klencke Barbara

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    4/17/26 4:15:02 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Knight Jeff E.

    3 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    4/17/26 4:10:03 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on ALX Oncology with a new price target

    Wells Fargo initiated coverage of ALX Oncology with a rating of Overweight and set a new price target of $5.00

    3/19/26 8:25:33 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS resumed coverage on ALX Oncology with a new price target

    UBS resumed coverage of ALX Oncology with a rating of Buy and set a new price target of $6.00

    3/6/26 8:38:03 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on ALX Oncology with a new price target

    Jefferies initiated coverage of ALX Oncology with a rating of Buy and set a new price target of $4.00

    11/13/25 9:09:54 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    Leadership Updates

    Live Leadership Updates

    View All

    ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer

    - Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (("ALX Oncology, NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, announced the appointment of Jeff Knight, M.P.H., as Chief Development and Operating Officer, effective April 13, 2026. "Jeff is a highly accomplished leader with deep expertise across clinical development and operations, and a strong track record of both advancing innovative thera

    4/13/26 8:30:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

    Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company's Board of Directors and will step down from the Board to join ALX as Interim Chief Medical Officer Alan Sandler, M.D. resigns as Chief Medical Officer and will return to his position serving on the Company's Board of Directors SOUTH SAN FRANCISCO, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced the appointment of Dr. Kl

    9/12/25 8:30:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors

    Mr. Shantharam is a proven biotech industry executive with over two decades of senior leadership experience in finance, commercial and corporate operationsDr. Klencke is a seasoned clinical leader in oncology drug development with more than 20 years of industry experienceDr. Takimoto brings a distinguished track record in oncology and drug development with 17 years of industry experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced the appointmen

    1/22/25 8:00:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    Financials

    Live finance-specific insights

    View All

    ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

    - Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination - - Evorpacept data from two independent HER2-positive trials strengthens confidence in the CD47-selection hypothesis and potentially derisks path forward in HER2-positive breast cancer - - Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer is on track for topline data mid-2027 - - Phase 1 trial evaluating ALX2004 continues to enroll well, on track for safety data in 2H 2026 -

    5/8/26 8:00:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression

    - Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - Findings are consistent with previous results from the randomized ASPEN-06 trial in HER2-positive gastric cancer, which indicated CD47 expression could potentially serve as an important predictive biomarker of evorpacept activity - - ALX Oncology will host a webcast on May 8 to report first quarter 2026 financial results; breast cancer expert will discuss the evorpacept + zanidatamab trial results in detail - SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (NASDAQ:ALXO), a clinical-stage biotechnology compa

    5/7/26 8:00:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026

    - Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ((", ALX Oncology", , NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that new data from the Phase 1b/2 clinical trial evaluating the company's investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceuticals' zanidatamab (ZIIHERA®) in heavily pretreated patients with HER2-positive metastatic breast cancer (mBC) will be presented at the ESMO Breast Cancer 2026 Congress in Berlin on Ma

    4/30/26 8:00:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

    SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

    11/14/24 7:22:54 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

    SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

    11/14/24 6:58:27 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

    SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

    11/14/24 3:02:41 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care